|
Staten Island Urological Research, P.C. |
|
Center Overview
Staten Island Urological Research, P.C. is a dedicated, independent, clinical urology research facility located in Staten Island, New York. It is the only facility of its kind in the area. The Medical Director is Ron S. Israeli, M.D., F.A.C.S., a board-certified academic urologist with extensive clinical and research specialty training in Urology and Urologic Oncology. The center is staffed by two fellowship-trained urologists and a fellowship-trained uro-gynecologist. Fields of interest represented by these investigators include Urologic Oncology, Impotence, Infertility, BPH, Incontinence, and Kidney Stone Disease and others. In addition, the center is indeed fortunate to posses another physician employed as Associate Medical Director, Barbara Minkowitz, M.D., as well as a highly experienced Senior Research Coordinator with over 17 years experience as a Urology Physician Assistant. Finally, in addition to the clerical staff, the center employs several full-time Physician Assistant clinical research coordinators. The intimate relationship between the center and our large and broad-based academic and private urology clinical practice enables easy access to an enormous database of potential urology patients spanning all diagnoses and demographic groups. Our group has an extensive clinical research experience in all areas of urology, especially benign prostate disease, prostate cancer, bladder cancer, prostatitis, impotence, infertility, incontinence, and urologic infections. We have established and maintained excellent relationships with many of the leading pharmaceutical and biotechnology companies in the field and are committed to bringing the latest and most exciting new research developments in the field of urology to our region.
Clinical Research Experience
Our center is comprised of expert physicians with extensive clinical and basic laboratory research, both in private practice as well as in some of the leading academic centers in the world including Johns Hopkins University, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, Boston University, Albert Einstein College of Medicine, and the Mt. Sinai School of Medicine. Dr. Israeli has over 60 published works in urology, and holds several patents related to urological discoveries. He lectures extensively and serves as a reviewer for several urologic journals. Dr. Minkowitz has published and lectured extensively on numerous subjects, and has received several coveted research awards in her field. Dr. Katlowitz is a well-known expert in erectile dysfunction and Infertility. He lectures regularly for Pfizer on treatment options for Male Sexual Dysfunction. Dr. Gil Levy is a fellowship-trained uro-gynecologist and serves as Director of Urogynecology/Female Pelvic Medicine at both Staten Island University Hospital and Maimonides Medical Center in Brooklyn, NY. Dr. Levy is well published in the field and has received numerous distinguished awards. He has a special interest in the development of new technologies for the treatment of incontinence.
Our center is relatively new as a formal research entity, but our collective experience has and will serve us well. We have been involved to date in clinical trials investigating new medications for impotence, chronic prostatitis, pre-malignant prostate disease, urinary retention, incontinence, prostate cancer, kidney cancer, and other areas.
Facility Description
Our research center is located in Staten Island, NY in a large, new modern dedicated office facility. The site is easily accessible by all forms of transportation and offers ample parking. The office is in close proximity to both Newark Liberty and JFK International airports. Modern, handicapped-accessible outpatient facilities are offered at our research center. These include a networked computer system with high speed internet service, phlebotomy services, IV infusions, secure drug storage, centrifuges, dry ice, dedicated 4°C refrigerator, -20°C freezer, -80°C freezer, urinalysis laboratory, abdominal and rectal ultrasound, cystoscopy, uroflow, cystometrography, microscopy, Doppler ultrasound, rigiscan, emergency medical equipment, and other supplies.
Investigator Experience
Medical Director:
Ron S. Israeli, M.D., F.A.C.S.
Associate Medical Director:
Barbara Minkowitz, M.D.
Principal Investigators:
Ron S. Israeli, M.D., F.A.C.S. Urologic Oncology and Prostate Disease
urology@si.rr.com
Barbara Minkowitz, M.D. Clinical Trials
bminkowitz@aol.com
Nachum Katlowitz, M.D., F.A.C.S. Erectile Dysfunction and Male Infertility
nkatlowitzmd@theurologists.com
Gil Levy, M.D., F.A.C.O.G. Female Incontinence/Pelvic Medicine
gillevy@optonline.net
Staff Expertise
Our staff includes 3 highly experienced Urology Physician’s Assistants serving as research coordinators, a physician research fellow (fully trained urologist), and clerical staff.
Patient Demographics
Staten Island is a unique location, positioned between Brooklyn and New Jersey. Our own borough has a diverse population of over 500,000 people. In addition, we attract large numbers of patients from surrounding areas, including New Jersey, Brooklyn, Manhattan, Queens, and other areas. Part of this attraction is the interest in the numerous, well advertised specialty programs offered by our principal hospital affiliation, Staten Island University Hospital, a major regional cancer center.
Other Information
We generally submit our trials to a central IRB for approval and have not presently contracted with any site management organizations.
Currently Enrolling Trials
CenterWatch is listing the following trials that are actively recruiting patients at this center.
- A clinical research study for patients with Overactive Bladder.
- A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind , Dose-Ranging Clinical Trial To Study The Efficacy And Safety of 5, 15 or 25mg/day CyPat (Cyproterone Acetate) for the Treatment of Hot Flashes Following Surgical or Medical Castration of Prostate Cancer Patients
- A Phase 3, Randomized, Open-label Study Evaluating DN-101 in Combination with Docetaxel in Androgen Independent Prostate Cancer (AIPC) (ASCENT2)
- A Randomized, Double Blind, Placebo Controlled Trial of Immunotherapy with Autologous Antigen-Loaded Dendritic Cells For Asymptomatic Metastatic Hormone Refractory Prostate Cancer.
- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men with Hormone Refractory Prostate Cancer
- A study with an experimental drug given each 6 months to help improve difficulty urinating due to an enlarged prostate
- AT ALL HOURS, the bathroom calls.
- Clinical Research Study for People with Cancer-related Anemia.
- Do you have any of these symptoms when you urinate?
- Do you have erectile dysfunction and lower urinary tract symptoms associated with BPH?
- Enlarged Prostate
- For Men Only
- For Men Only: Have you had a suspicious prostate biopsy, like Prostate Intrapithelial Noplasia (PIN)?
- Prostate Cancer Bone Loss Study.
- Prostate Cancer Prevention Clinical Trial
- Prostate cancer trial
- Tired of Missing The Big Game?
- Urinary Incontinence Study
Contact Information
For more information, please contact:
Ron S. Israeli, M.D., F.A.C.S.
Staten Island Urological Research, P.C.
1800 Clove Road
Staten Island, NY 10304 USA
Phone: 718-720-6040
Fax: 718-720-6523
E-mail:
If you are interested in contacting this center to discuss placing a clinical trial there, please complete and send the E-mail form below. A representative from the research center will then follow up with you.
